93 related articles for article (PubMed ID: 21252722)
1. Dramatic response to pemetrexed in a patient with pneumonic-type mucinous bronchioloalveolar carcinoma.
Garfield DH; Franklin W
J Thorac Oncol; 2011 Feb; 6(2):397-8. PubMed ID: 21252722
[No Abstract] [Full Text] [Related]
2. Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity.
Okuda C; Kim YH; Takeuchi K; Togashi Y; Masago K; Sakamori Y; Mio T; Mishima M
J Thorac Oncol; 2011 Mar; 6(3):641-2. PubMed ID: 21317746
[No Abstract] [Full Text] [Related]
3. A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma.
Yamakawa H; Takayanagi N; Ishiguro T; Kagiyama N; Shimizu Y; Sugita Y
Intern Med; 2013; 52(24):2781-4. PubMed ID: 24334585
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.
Ho C; Ross H; Davies A
Clin Lung Cancer; 2006 Nov; 8(3):220-2. PubMed ID: 17239300
[No Abstract] [Full Text] [Related]
5. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
6. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Manson GV; Ma PC
Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
[TBL] [Abstract][Full Text] [Related]
7. The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Pérol M; Arpin D
Curr Drug Targets; 2010 Jan; 11(1):74-7. PubMed ID: 19839924
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-induced skin sclerosis.
Merklen-Djafri C; Imbert E; Courouge-Dorcier D; Schott R; Méraud JP; Muller C; Tebacher M; Springinsfeld G; Cribier B; Lipsker D
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):452-3. PubMed ID: 22397832
[No Abstract] [Full Text] [Related]
9. More than 54 months survival of a patient with lung adenocarcinoma after maintenance therapy with pemetrexed.
Samelis G; Ekmektzoglou K; Giannakaki S; Tsiakou A
J BUON; 2010; 15(4):797. PubMed ID: 21229649
[No Abstract] [Full Text] [Related]
10. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed disodium.
Muhsin M; Gricks C; Kirkpatrick P
Nat Rev Drug Discov; 2004 Oct; 3(10):825-6. PubMed ID: 15497247
[No Abstract] [Full Text] [Related]
12. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed-induced anaphylaxis.
Shah BK; Hewett Y
Acta Oncol; 2013 May; 52(4):881. PubMed ID: 23472834
[No Abstract] [Full Text] [Related]
15. [Clinical case of the month. The "classic" triad presentation of mucinous bronchiolo-alveolar carcinoma].
Figiel S; de Leval L; Rousié C; Duysinx B; Louis R; Defraigne JO; Radermecker M
Rev Med Liege; 2010 Nov; 65(11):611-4. PubMed ID: 21189525
[TBL] [Abstract][Full Text] [Related]
16. [Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma].
Wang ZK; Hu Y; Zhao H; Fu C
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):978-80. PubMed ID: 20501373
[TBL] [Abstract][Full Text] [Related]
17. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases.
Ochi N; Yamane H; Yamagishi T; Takigawa N
Lung Cancer; 2013 Apr; 80(1):111-3. PubMed ID: 23279874
[No Abstract] [Full Text] [Related]
18. Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
Tamura K; Fujiwara Y
Asia Pac J Clin Oncol; 2010 Dec; 6(4):248-50. PubMed ID: 21114772
[No Abstract] [Full Text] [Related]
19. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
20. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
Pistillucci G; Sciacca V; Ciorra A; Di Palma T; Calabretta F; Lugini A; Rossi R; D'Aprile M; Veltri E
Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
